First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study

Table 4 Adverse events of any cause during TPEx treatment

Event, n (%)	TPEx (n = 24)
	Any grade	Grade 3	Grade 4
Any treatment-related adverse event1	18 (75)	6 (25)	0
Hematological
Febrile neutropenia	3 (12.5)	3 (12.5)	0
Anemia	3 (12.5)	0
Hyponatremia and/or hypokalemia	3 (12.5)	2 (8.3)	0
Hypomagnesemia	2 (8.3)	1 (4.2)	0
Thrombocytopenia	1 (4.2)	0	0
Nonhematological
Acne-like rash	8 (33.3)	0	0
Nausea - vomiting	4 (16.7)	1 (4.2)	0
Asthenia	4 (16.7)	1 (4.2)	0
Diarrhea	2 (8.3)	0	0
Renal failure	1 (4.2)	1 (4.2)	0
Hypersensitivity	1 (4.2)	0
Oral mucositis	1 (4.2)	0	0
Any serious adverse event2	-	5 (20.8)	0
Treatment-related death	0	-	-
Event leading to interruption of any treatment component3	3 (12.5)	-	-
Chemotherapy	2 (8.3)	-	-
Cetuximab	1 (4.2)	-	-
Event leading to discontinuation of any treatment component3	2 (8.3)	-	-
Chemotherapy	2 (8.3)	-	-
Cetuximab	0
Event leading to dose reduction	2 (8.3)	-	-

¹The investigators determined whether adverse events were related to the treatment.

²Adverse events that lead to hospitalization.

³This category includes patients who experienced cisplatin, docetaxel, or cetuximab treatment interruption or discontinuation because of an adverse event at any time and patients who experienced cetuximab maintenance therapy interruption or discontinuation for an adverse event after completing the chemotherapy cycles.

Events were attributed to the specific treatment by the investigator.